Compounded semaglutide and tirzepatide (US): safety, legality basics, and red flags for patients

ByGLP1-Consultant

TL;DR

  • FDA-approved GLP‑1/dual-incretin brands include Wegovy/Ozempic (semaglutide) and Zepbound/Mounjaro (tirzepatide).
  • Compounded versions are custom-prepared by certain pharmacies; they do not undergo FDA approval for safety/effectiveness the way branded products do.
  • The FDA has raised concerns about:
    • dosing errors (especially with multi-dose vials)
    • quality/sterility issues
    • products made with different forms of semaglutide (e.g., salts)
    • misleading marketing and unsafe online purchasing
  • If cost or shortages are driving your decision, the safest path is a clinician-guided plan using a properly licensed U.S. pharmacy with clear labeling and dosing instructions.

Key takeaways

  • “Compounded semaglutide” is not automatically equivalent to Wegovy/Ozempic.
  • The largest real-world risk is often incorrect dosing, not just “side effects.”
  • You can reduce risk by verifying the pharmacy, understanding the exact concentration, and having follow-up support for side effects.

Short answer

Compounded semaglutide or tirzepatide is a pharmacy-prepared version that is not the same as FDA-approved brand-name products. The FDA has warned about reports of dosing errors and about some compounded products made with different forms of semaglutide (salts) that are not the FDA-approved active ingredient. Patients considering compounded GLP‑1 medications due to cost or availability should discuss risks and alternatives with a licensed clinician, verify the pharmacy’s credentials, and make sure dosing instructions are clear and precise.

Why people look for compounded GLP‑1 medications

Patients commonly consider compounded products because:

  • insurance won’t cover FDA-approved weight-loss drugs
  • cash prices are high
  • local pharmacies can’t reliably stock certain doses
  • they hear about “the same drug for cheaper” on social media

These pressures are real. The goal of this guide is not to shame people—it’s to help you understand the tradeoffs and safety risks so you can make a more informed decision with your clinician.

If you’re deciding between FDA-approved options first, start here:

What does “compounded” mean?

Compounding generally refers to a pharmacy creating a medication by combining, mixing, or altering ingredients to tailor therapy for a specific patient.

Compounding can be important for legitimate needs (examples):

  • a patient needs a dose or formulation not commercially available
  • a patient has an allergy to an inactive ingredient in the FDA-approved product

However, compounded drugs are generally not FDA-approved, and the FDA does not review them for safety/effectiveness/quality the same way it reviews commercially manufactured drugs.

FDA overview: https://www.fda.gov/drugs/human-drug-compounding

The FDA’s key concerns (in plain English)

1) Dosing errors (a major, practical risk)

Many compounded GLP‑1 medications are dispensed in multi-dose vials, and patients measure doses using syringes.

Common dosing pitfalls:

  • mixing up mg, mL, and “units”
  • not realizing that two vials can have different concentrations
  • using the wrong syringe (e.g., insulin syringe vs tuberculin syringe)

Why it matters:

  • an accidental high dose can cause intense vomiting and dehydration
  • dehydration can lead to urgent care/ER visits and kidney complications

If you’re already experiencing side effects, see GLP‑1 side effects.

2) “Semaglutide salts” and ingredient confusion

Some compounded products have been marketed as semaglutide sodium or semaglutide acetate.

The FDA has warned that these may not be the same as the active ingredient in the FDA-approved drugs.

Patient takeaway: If your product label includes wording that doesn’t match the FDA-approved ingredient, treat that as a serious discussion point with your clinician and pharmacist.

3) Sterility and contamination

Injectable medications must be sterile. Poor compounding practices can cause contamination.

Patient takeaway: You should be able to identify the pharmacy, verify its credentials, and receive clear storage and beyond-use dating.

4) Misleading marketing and unsafe online purchasing

Some online sellers:

  • refuse to disclose sourcing
  • offer “semaglutide” without a real prescription
  • bundle medication with a subscription model that minimizes clinical follow-up

FDA BeSafeRx (how to buy from online pharmacies more safely): https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information

503A vs 503B (what patients should know without getting lost in legal details)

In the U.S., compounding rules vary based on the type of facility.

  • 503A pharmacies generally compound patient-specific prescriptions.
  • 503B outsourcing facilities can compound larger batches under a different regulatory framework.

Patient takeaway: whichever type is involved, you should still ask:

  • “Who exactly is compounding this?”
  • “How is sterility and quality assured?”
  • “What is the exact concentration and dosing instruction?”

(If the seller can’t answer clearly, that’s a red flag.)

Red flags checklist (save this)

Product and pharmacy red flags

  • The seller won’t provide the pharmacy name, address, and license.
  • The medication arrives without:
    • drug name and concentration
    • lot number/beyond-use date
    • storage instructions
  • The label uses unclear dosing language (e.g., only “units” with no mg/mL).
  • The medication is shipped warm when refrigeration is expected.

Clinical red flags

  • No medication review for contraindications (MTC/MEN2, pancreatitis history, etc.).
  • No plan for dose escalation or side-effect follow-up.
  • You’re told to increase dose quickly despite vomiting or severe nausea.

Safer questions to ask (bring to your clinician/pharmacist)

  1. “Is there an FDA-approved option I can access first?”
  2. “What exactly is the active ingredient and where is it sourced?”
  3. “What’s the concentration (mg/mL), and what is my dose in mg and mL?”
  4. “Which syringe should I use, and can you show me how to measure it?”
  5. “What is the beyond-use date and how should I store it?”
  6. “What side effects are expected vs urgent?”

What to do if you suspect a dosing error or contaminated product

  • If you have severe vomiting, severe abdominal pain, trouble breathing, or can’t keep fluids down, seek urgent medical care.
  • Contact your clinician promptly for guidance.
  • If you suspect product quality issues, consider reporting through FDA pathways (your clinician or pharmacist can help).

Frequently asked questions

Is compounded semaglutide or tirzepatide “FDA approved”?

No. Compounded drugs are generally not FDA-approved in the way branded drugs are.

Is compounded semaglutide always unsafe?

Not necessarily, but it carries different risks than FDA-approved products—especially dosing accuracy and quality variability. Risk depends on the pharmacy, the formulation, and how dosing is handled.

Why is dosing harder with vials?

Prefilled pens deliver set doses. Vials require you to measure the dose manually, which increases the chance of error.

If my insurance won’t cover Wegovy/Zepbound, what are my options?

Options can include insurance appeals, different FDA-approved medications, lifestyle programs, or other clinician-guided strategies. The best path depends on your medical history and coverage.

References

Medical disclaimer

This article is for general educational purposes only and does not replace medical advice. Do not start, stop, or change prescription medications without guidance from a licensed clinician. For emergencies, call 911.